Grants FY24-25 | Singapore National Eye Centre

NMRC

“A Model for Myopic Traction Maculopathy Progression Based on Retinal Biomechanics”
Assoc Prof Donny Hoang; S$1,499,998.00
“The Singapore Epidemiology of Eye Diseases (SEED) Study 4: Prospective multi-ethnic cohort study of 20-year incidence, progression, and risk factors of major eye diseases in elderly Asians”
Prof Cheng Ching Yu; S$1,500,000.00
“Novel Imaging Biomarkers for Myopia”
Prof Leopold Schmetterer; S$1,250,000.00
“Translational Asian Age-related Macular Degeneration Program Phase 2 (TAAP-2)”
Prof Gemmy Cheung; S$19,230,769.20
“Characterization of the Retinal Microvascular Endothelial Cell Response to Biomechanical Deformation”
Dr Rachel Chong; S$1,496,980.00
“Elucidating the Pathogenic Mechanism and Evaluate Management Strategies of ‘Pachychoroid Disease Spectrum’”
Prof Gemmy Cheung; S$3,461,538.45
“Risk Factors for Structural and Functional Losses Associated with Myopia-Associated Optic Neuropathy”
Dr Rachel Chong; S$675,000.00
“Optimising and assessing electrical stimulation of the Optic nerve - The Aeson Study”
Dr Fiona Lim; S$200,000.00
“Developing a Genetic Treatment Strategy for GUCY2D-Related Autosomal Dominant Cone-Rod Dystrophy”
Dr Tan Tien En; S$782,000.00
“The Role of Peroxisome Proliferator-activated Receptors-α Agonists in Promoting Corneal Nerve Trophic Function and Nerve Regeneration”
Assoc Prof Liu Yu Chi; S$1,287,979.00
“Investigating the role of UBOX5 in Primary Angle Closure Glaucoma”
Prof Aung Tin; S$1,500,000.00
“A Potential Window into Diabetic Microvascular Complications”
Assoc Prof Liu Yu Chi; S$675,000.00
“Development, Validation, and Testing of DR-GPT - A Multi-model Generative AI Agent for Diabetes Eye Care in Primary and Tertiary Eye Care Settings”
Assoc Prof Daniel Ting; S$1,750,000.00
“The Effects of Ripasudil in patients with Fuchs Endothelial Corneal Dystrophy undergoing Femtosecond Laser Assisted Cataract Surgery”
Assoc Prof Marcus Ang; S$675,000.00
“Effect of Light on Atropine response in Myopic children”
Assoc Prof Audrey Chia; S$674,828.40
“Singapore lYMPHoma translatiONal study (SYMPHONY) 2.0 - Theme 1 (Subaward)”
Dr Anita Chan; S$346,153.85
“Addressing Barriers to Data In Ophthalmology with Generative Artificial Intelligence”
Dr Damon Wong; S$1,250,000.00

A*Star/ Duke-NUS/ MOH/ Others

“Monitoring of Patients with Advanced Glaucoma”
Assoc Prof Jacqueline Chua; S$125,000.00
“Development of the Polarisation-Sensitive Optical Coherence Tomography”
Prof Leopold Schmetterer; S$230,000.00
“Singapore Strategic Cohorts Consortium”
Prof Cheng Ching Yu; S$3,329,907.00
“Good Manufacturing Practice (GMP) Production of Human Corneal Stromal Keratocytes from Donor Tissue for Cellular Therapeutics: Quality Control and Validation”
Prof Jodhbir Mehta; S$50,000.00
“Implementation of an Artificial Intelligence-Enabled Platform for the Prediction of High Myopia in Singapore Children”
Assoc Prof Marcus Ang; S$599,000.00
“OPTIZS - OPhthalmic Tech Innovation by Zeiss and SERI”
Prof Jodhbir Mehta; S$5,033,840.00

SingHealth

“Phenotyping Asian Macular Diseases - A Prospective Functional and Angiography Study of the Clinical Course of Three Common Acquired Retinal Conditions in an Asian Population (Phenotyping AMD)”
Prof Gemmy Cheung; S$250,000.00
“Spatiotemporal Transcriptomic Signature of Cultivated Human Corneal Stromal Keratocytes in Vitro And in Mouse Model of Acute Corneal Opacity”
Dr Andri Riau; S$60,000.00
“Targeting Fibroblasts to Unveil Retinoic Acid Signaling in Myopic Eye Growth”
Dr Jiang Liqin Susan; S$150,000.00
“Combination of Trained Bacteriophages and Antibiotics to Tackle Multi-drug Resistant Methicillin-Resistant Staphylococcus Aureus (MRSA) Infectious Keratitis”
Dr Thet Tun Aung; S$149,990.60
“Investigation of Scleral Collagen Remodeling During the Development of Staphyloma in Guinea Pigs Using Tripleinput Polarization Sensitive Optical Coherence Tomography”
Dr Liu Xinyu; S$50,000.00
“Self-Correcting OCT Image Enhancer”
Dr Munirah Ismail; S$79,933.00
“Pupil Dynamics in Primary Angle Closure Disease (PD)”
Dr Tin Aung Tun; S$150,000.00

Commercial

“A Phase IIIb/IV, Multicenter, Randomized, Open-label, Two-arm Study to Investigate the Efficacy, Safety, and Durability of Faricimab Administered up to Every 24 weeks in Patients with Neovascular Age-related Macular Degeneration (Constance)”
Prof Gemmy Cheung; S$523,687.93
“Efficacy, Safety and Tolerability of Nanoliposomal Latanoprost (Lipolat) Injections for Treatment of Ptosis: A Pilot Study”
Dr Chung Hsi-Wei; S$63,315.67
“Development of Retinopathy of Prematurity (ROP) Model in Marmosets for Therapy Testing and Mechanism Evaluation”
Assoc Prof Amutha Barathi; S$ 14,044.16
“Light and Myopia: Interactions Between Light Patterns and Intensity”
Assoc Prof Amutha Barathi, Dr Raymond Najjar; S$100,000.00
“MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)”
Assoc Prof Gavin Tan; S$8,544.51
“JARVIS-DHL: Transforming Chronic Care for Diabetes, Hypertension and hyperLipidemia with AI (Stage 2b)”
Assoc Prof Gavin Tan; S$268,344.00
“A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2”
Dr Natalia Porporato; S$16,155.66
“Randomized, Controlled, Open-label, Phase 3, Global Multi-Center Trial to Assess the Efficacy and Safety of Zipalertinib plus Chemotherapy versus Chemotherapy alone, in Patients with Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations – REZILIENT3”
Dr Natalia Porporato; S$5,817.33
“A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants with Advanced Solid Tumors”
Dr Natalia Porporato; S$10,957.77
“REF 1: Smile Advanced Vision Correction Examination of Outcomes (SAVEO)“
Prof Jodhbir Mehta; S$3,175,583.54
“SAS 1: Develop Ocular Surface Disease (OSD) Diagnostics, Algorithms, And Management Protocols for Cataract Surgery”
Prof Louis Tong; S$1,089,793.96
“Evaluation of Compound X-039 on Glaucoma Management and Neuroprotection”
Prof Tina Wong; US$299,185.50
“SAS 2: Developing an Accommodating Intraocular Lens (AIOL) with an Open Capsular Bag Concept”
Assoc Prof Shamira Perera; S$1,090,206.04
“Soft Contact Lens-Atropine Combination Therapy in Children Randomised Controlled Trial”
Assoc Prof Audrey Chia; S$1,780,493.65
“New Drug Targets for Myopia: GABA Antagonists and Vasodilating Agents”
Assoc Prof Amutha Barathi: S$819,506.35
“A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)”
Dr Natalia Porporato; S$39,154.98
“A Phase 2, Open-Label, Randomized, Global Study of Two Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (M25-274)”
Dr Natalia Porporato; S$6,834.30
“MAGNITUDE-2: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)”
Dr Beau James Fenner; S$19,122.96
“Corneal Endothelial Images Analysis for Automatic Assessment of Cornea Transplant Viability”
Assoc Prof Liu Yu Chi; S$1,872.50